Myeloma

HittPack™

A search of the latest news and medical research findings

October 03, 2011
## Contents

I. Disease and Treatment Information in Myeloma ................................................................. 2

II. Recent News Articles in Myeloma .......................................................................................... 2
   Medscape Medical News (free password required) .................................................................. 2
   MedpageToday .......................................................................................................................... 3
   Reuters ................................................................................................................................... 4

III. Press Releases in Myeloma .................................................................................................... 6
   Eurekalert.org .......................................................................................................................... 6
   Newswise.com ........................................................................................................................ 11
   Google.com ............................................................................................................................. 15

IV. US Food and Drug Administration Info on Myeloma .......................................................... 17
   Drugs@FDA Database ........................................................................................................... 17
   2011 Advisory Committee Meetings ....................................................................................... 20

V. Guidelines in Myeloma .......................................................................................................... 20
   National Guidelines Clearinghouse--Guidelines.gov ............................................................... 20
   National Comprehensive Cancer Network ............................................................................. 23
   American Society of Clinical Oncology ................................................................................ 23

VI. Conferences and Medical Associations for Myeloma ......................................................... 24
   Conferences ............................................................................................................................ 24
   Medical Associations ............................................................................................................ 24

VII. Key Opinion Leaders in Myeloma ...................................................................................... 24

VIII. Clinical Trials in Progress in Myeloma ........................................................................... 25

IX. PubMed Search in Myeloma ................................................................................................ 36
   Randomized Controlled Trials .............................................................................................. 36
   Reviews .................................................................................................................................... 39
   Editorials ................................................................................................................................. 54
I. Disease and Treatment Information in Myeloma

- **National Cancer Institute** - General Information About Multiple Myeloma/Other Plasma Cell Neoplasms
  http://www.cancer.gov/cancertopics/types/myeloma
- **American Cancer Society** – Multiple Myeloma detailed guide
  http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index
- **American Society of Clinical Oncology** - Multiple Myeloma
  Oncologist-approved cancer information from the American Society of Clinical Oncology
  http://www.cancer.net/patient/Cancer+Types/Multiple+Myeloma
- **emedicine.medscape.com** – Multiple Myeloma

II. Recent News Articles in Myeloma

**Medscape Medical News (free password required)**

http://www.medscape.com/; search term = myeloma; all results for the past 3 months.

- **Tandem Autologous-Allogeneic Stem-Cell Transplants for Myeloma Improve Survival**
  Patients with previously untreated multiple myeloma do better when they're given an autologous stem-cell transplant followed by an allogeneic transplant ... News, Reuters Health Information, July 2011

- **With New Induction Drugs for Multiple Myeloma, Still OK to Delay Stem Cell Transplant**
  In patients with multiple myeloma treated initially with new immunomodulatory drugs, delaying stem cell transplantation won't affect overall survival, a ... News, Reuters Health Information, September 2011

- **Bone Marrow Involvement Predicts Progression to Symptomatic Myeloma**
  ... make up at least 60% of the bone marrow, the odds of smoldering multiple myeloma progressing to symptomatic myeloma rise dramatically, researchers report ... News, Reuters Health Information, August 2011

- **Surprise: Lenalidomide May Interact With P-Glycoprotein**
  ... properties, is a standard treatment for initial and relapsed multiple myeloma. Temsirolimus, which has been approved for the treatment of renal cell ... News, Medscape Medical News, August 2011
• **Lenalidomide Has Positive Benefit/Risk Ratio, Says EMA**... with dexamethasone for the second-line treatment of adults with multiple myeloma who have failed at least 1 previous therapy. The review followed ... News, Medscape Medical News, September 2011

• **Johnson & Johnson Warns of Doxil (doxorubicin) Shortage**... Boehringer Ingelheim and used to treat ovarian cancer and multiple myeloma. Doxil is among a growing number of drugs made by specialty drugmakers ... News, Reuters Health Information, July 2011

• **Incidence of Thromboembolic Events With Cisplatin Too High**... Patients who receive either of these drugs for the treatment of multiple myeloma have an 18% to 22% risk for thrombosis. In fact, it is recommended that ... News, Medscape Medical News, September 2011

• **Bendamustine/rituximab Helpful in Refractory Leukemia**... has been used in Germany for more than 40 years to treat multiple myeloma, non-Hodgkin’s lymphoma and solid cancers. It was recently approved in ... News, Reuters Health Information, August 2011

• **Denosumab Approved in EU for Cancer With Bone Metastases**... and in a third trial in patients with other solid tumors or multiple myeloma and bone metastases (J Clin Oncol. 2011;29:1125-1132), denosumab was ... News, Medscape Medical News, July 2011

• **Is Benefit of Bortezomib in Follicular Lymphoma Worthwhile?**... Oncology. Bortezomib was originally licensed for use in multiple myeloma; last year, it’s label was updated to include data on survival benefit. ... News, Medscape Medical News, August 2011

• **Deaths From Prescription Opioids on the Rise**... in 2007. Such deaths are now more common than deaths from multiple myeloma, HIV, and alcoholic liver disease. Oxycodone Particularly Dangerous A ... News, Medscape Medical News, August 2011

---

**MedpageToday**

http://www.medpagetoday.com/; search term = myeloma; all results for the past 3 months.

**ECCO-ESMO: Study Finds Target for Multiple Myeloma Treatment**

9/28/2011
Russian researchers suggested here that a molecular analysis of plasma cells from patients with multiple myeloma might give clues about when targeted therapies would be most appropriate.

**ECCO-ESMO: Bone Drug’s Benefits Consistent in Myeloma**

9/28/2011
The survival and skeletal benefits of treatment with an intravenous bisphosphonate remained consistent across a population of patients with multiple myeloma, subgroup analysis of a large clinical trial showed.

**ECCO-ESMO: Model May Predict Drug Success in**
**ECCO-ESMO: Stem Cell Therapy Still Multiple Myeloma Mainstay**  
9/28/2011

Although new drugs have proven effective in multiple myeloma, results of a phase III study confirmed that autologous stem cell transplantation remains a therapeutic bedrock for newly diagnosed disease, researchers found.

---

**Lab Notes: Building a Better Knee**  
9/28/2011

Bortezomib is a proteasome inhibitor currently used against multiple myeloma and lymphoma, but, in vitro, it also blocks production of fibrotic proteins involved in both pulmonary fibrosis and scleroderma.

---

**Myeloma...**  
9/28/2011

A modeling simulation based on interim reduction in M-protein can predict outcomes in multiple myeloma patients being treated with the investigational drug pomalidomide, researchers suggested here.

---

**Reuters**

[www.reuters.com; search term = myeloma; all results for the past 3 months.](http://www.reuters.com)

**J&J sees continued supply shortages of cancer drug**

... The injectable drug, which had annual global sales of about $500 million as of July, is used to treat ovarian cancer and multiple myeloma. ...

**Wed Sep 28, 2011 1:59am EDT**

**Celgene shares jump ahead of EU drug safety review**

... It is approved in the United States and Europe, in combination with dexamethasone, to treat patients with multiple myeloma who have failed at least one ...

**Tue Sep 20, 2011 2:50pm EDT**

**UPDATE 1-Celgene shares jump ahead of EU drug safety review**

... It is approved in the United States and Europe, in combination with dexamethasone, to treat patients with multiple myeloma who have failed at least one ...
MorphoSys Announces Clinical Milestone in Cancer Antibody Program ...

... rheumatoid arthritis, MOR208, which is in a Phase 1/2a trial for chronic lymphocytic leukemia and MOR202, which is in a Phase 1/2a trial for multiple myeloma. ...

Gene therapy shown to destroy leukemia tumors

... The results provide "a tumor-attack roadmap for the treatment of other cancers," including those of the lung and ovaries as well as myeloma and melanoma ...

Revlimid side effects linked to protein in study

... LOS ANGELES, Aug 8 - An early-stage trial of Celgene Corp’s <CELG.O> multiple myeloma drug Revlimid has found that it interacts with another protein that ...

Celgene second quarter profit rises; ups 2011 forecast

... Sales of Revlimid, the company’s drug to treat multiple myeloma and most important growth driver, rose 35 percent to $795 million as physicians increasingly ...

J&J warns doctors of Doxil cancer-drug shortage

... The injectable drug, which has annual global sales of about $500 million, is used to treat ovarian cancer and multiple myeloma. ...
... major conferences. Better outcomes were achieved with Revlimid maintenance in newly diagnosed multiple myeloma patients. This news ...

Thu Jul 21, 2011 1:31am EDT

III. Press Releases in Myeloma

Eurekalert.org

www.eurekalert.org; search term = myeloma; first 20 results.

John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
... of personalized treatments for multiple myeloma ... segments and variations of multiple myeloma. The study is the centerpiece of the Multiple Myeloma Research Foundation's (MMRF) Personalized ...

Novel approach scores first success against elusive cancer gene
... The results, achieved in multiple myeloma cells, offer a promising strategy ... strategy for treating not only myeloma but also many other cancer ... namesake of JQ1. In multiple myeloma, MYC is hyperactive – constantly ordering ...

Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
... new tool to counter multiple myeloma drug resistance ... individualized patient treatments for multiple myeloma. The technique has potentially broader ... Multiple myeloma is an incurable malignancy in ...
http://www.eurekalert.org/pub_releases/2011-09/hlmc-
### Subcutaneous injection of bortezomib: A promising and safer alternative to intravenous delivery in patients with multiple myeloma

Treatment in patients with multiple myeloma (cancer of the bone marrow) newly diagnosed and relapsed multiple myeloma. As an alternative to the...


| 67% | 18 Apr 11 |

### Researchers sequence multiple myeloma genome in landmark Nature study

... Researchers sequence multiple myeloma genome in landmark Nature study ... Ph.D., Co-Chief, Multiple Myeloma John Theurer Cancer Center part ... complete genomic portrait of multiple myeloma, a highly aggressive blood cancer ...


| 71% | 23 Mar 11 |

### First look at the full multiple myeloma genome reveals new insights, discoveries

... look at the full multiple myeloma genome reveals new insights, discoveries ... 40 tumor genomes points multiple myeloma research in new directions ... full genetic blueprint of multiple myeloma, a form of blood cancer ...


| 68% | 23 Mar 11 |

### The MMRF and John Theurer Cancer Center to host patient symposium

... and workshops from leading multiple myeloma specialists ... March 16, 2011) — The Multiple Myeloma Research Foundation (MMRF) and the ... Center, member of the Multiple Myeloma Center...

| 70% | 17 Mar 11 |
Research Consortium (MMRC), will host ...

**VCU Massey first to combine targeted agents to kill multiple myeloma cells**
... targeted agents to kill multiple myeloma cells ... novel treatment strategy for multiple myeloma that pairs two targeted agents ... to demonstrate the synergistic, anti-myeloma effects of this combination regimen ...

**Drug combination shows promise for newly diagnosed blood cancer patients, study finds**
... treat the blood cancer multiple myeloma may be effective as a line treatment of patients with myeloma, a type of cancer that ... D., director of the multiple myeloma program at the University of ...

**Study identifies key molecules in multiple myeloma**
... identifies key molecules in multiple myeloma ... often turned off in multiple myeloma, a presently incurable cancer of ... leads to the death of myeloma cells and could provide a ...

**High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in ...**
... new drug and stem cells in myeloma The ... to treating newly diagnosed multiple myeloma has found that both treatments ... patients with newly diagnosed multiple myeloma. ...
http://www.eurekalert.org/pub_releases/2010-10/esfm-hrr100910.php- 7.7KB -
**TGen-Mayo Clinic study discovers role of DNA methylation in multiple myeloma blood cancer**

... of DNA methylation in multiple myeloma blood cancer ... Report finds development of multiple myeloma is tied to 'hypomethylation' ... new ways of treating multiple myeloma by targeting the multiple myeloma epigenome. This study also emphasizes ...


---

**New discovery brings hope to treatment of incurable blood cancer**

... Multiple myeloma is one of the most ... development and progression of multiple myeloma. The study was done in ... Using large cohorts of myeloma patients the researchers have identified ...


---

**Arizona Myeloma Network presents 'Special Award' to TGen president**

... Arizona Myeloma Network presents 'Special Award' to ... July 1, 2010 — The Arizona Myeloma Network (AzMN) has presented a ... in the 2nd annual Arizona Myeloma Network Race for Hope ...


---

**New myeloma drug shows promise in early testing**

... New myeloma drug shows promise in early ... appears promising in treating multiple myeloma, a type of blood cancer ... chemotherapies approved to treat multiple myeloma, a cancer that arises in ...


---

**Vertebroplasty: Integral to treating back pain in blood marrow cancer patients**

... fractures in those with multiple myeloma, says largest study to date ... fractures in
patients with multiple myeloma, a blood cancer, shows that ... the complicated
treatment of multiple myeloma, an incurable (yet treatable) cancer ...  
http://www.eurekalert.org/pub_releases/2010-03/soir-vit030410.php- 11.5KB -  
Public Press Releases

**Drug shows positive responses, low side-effects in multiple myeloma**  
... low side-effects in multiple myeloma ... adverse side effects among multiple  
myeloma patients in a phase II ... with relapsed or resistant multiple myeloma who  
have received one to ...  
http://www.eurekalert.org/pub_releases/2009-12/utom-dsp_1120509.php- 9.8KB -  
Public Press Releases

**Multiple myeloma patients experience high response rate with new 3-drug  
combination**  
... Multiple myeloma patients experience high response rate ... patients newly  
diagnosed with multiple myeloma, a cancer of white blood ... be highly effective in  
multiple myeloma patients who had relapsed or ...  
http://www.eurekalert.org/pub_releases/2009-12/dci-mmp120409.php- 8.7KB -  
Public Press Releases

**IMF teleconference: An advance look at multiple myeloma at ASH 2009**  
... An advance look at multiple myeloma at ASH 2009 ... Emerging myeloma  
therapies set stage for treating ... for Aptium Oncology, the International Myeloma  
Foundation’s International Myeloma Working Group and the Myeloma Committee  
of the Southwest Oncology ...  
Press Releases

**Lower-dose dexamethasone can be used to treat newly diagnosed myeloma**  
... used to treat newly diagnosed myeloma ... mainstay of therapy for multiple  
myeloma. However, a study published Online ... in patients with newly diagnosed  
myeloma; and is thus a viable ...  
Press Releases
**Blood Pressure Drugs May Lengthen Lives of Melanoma Patients**

**Ohio State University**

2011-09-20

Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

**Novel Approach Scores First Success Against Elusive Cancer Gene**

**Dana-Farber Cancer Institute**

2011-09-09

Dana-Farber researchers successfully disrupted the function of the gene MYC by tampering with the gene's "on" switch and growth signals in multiple myeloma cells, offering promising strategy for treating myeloma and other cancers driven by the MYC gene.

**Researchers Use New Tool To Counter Multiple Myeloma Drug Resistance**

**Moffitt Cancer Center**

2011-09-09

Moffitt Cancer Center researchers, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of acquired drug resistance and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

**Researchers at UT Southwestern find way to help donor adult blood stem cells overcome transplant rejection**

**UT Southwestern Medical Center**

2011-08-03

Findings by UT Southwestern Medical Center researchers may suggest new strategies for successful donor adult stem cell transplants in patients with blood cancers such as leukemia, lymphoma and myeloma.

**It’s in the Sugar: Mayo Clinic Shows How Metabolism Affects Stem Cell Cultivation**
Mayo Clinic

2011-08-01

Providing new insight into the biomechanics of regenerative medicine, researchers at Mayo Clinic have shown how cellular metabolism facilitates stem cell procurement from regular tissue.

Specialized Regulatory T Cell Stifles Antibody Production Centers

University of Texas M. D. Anderson Cancer Center

2011-07-25

A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, a team led by scientists at The University of Texas MD Anderson Cancer Center reported online in the journal Nature Medicine.

Statewide Cord Blood Bank Celebrates Grand Opening at UAMS

University of Arkansas for Medical Sciences

2011-07-19

Celebrating the grand opening of the Cord Blood Bank of Arkansas at the University of Arkansas for Medical Sciences (UAMS) today, Brian and Jennifer Odle told how the use of cord blood gave their 18-month-old daughter a new lease on life.

Patient Partnership: A Powerful Shift in Health Care Delivery at UAMS Myeloma Institute

University of Arkansas for Medical Sciences

2011-06-23

A new model of care developed for patients at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience, lower costs and better patient outcomes.

Device Could Improve Harvest of Stem Cells from Umbilical Cord Blood

Johns Hopkins University

2011-06-20

A graduate student team has invented a system to significantly boost the number of stem cells collected from a newborn’s umbilical cord and placenta, so that many more patients with leukemia, lymphoma and other blood disorders can be treated.
NewYork-Presbyterian/Weill Cornell Research Presented at American Society of Clinical Oncologists Meeting

NewYork-Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

2011-06-03

Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The meeting takes place June 3–7, at McCormick Place, Chicago.

Prepared Patient: Watchful Waiting — When Treatment Can Wait

Health Behavior News Service

2011-06-01

When it comes to certain medical conditions, delaying treatment while regularly monitoring the progress of disease — a strategy doctors refer to as “watchful waiting,” active surveillance or expectant management — may benefit some patients more than a rush to pharmaceutical or surgical options.

Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients

University of Texas M. D. Anderson Cancer Center

2011-05-31

Landmark study of personalized therapy may lead to a “flood of new agents.”

Treatment with Lenalidomide After Stem-Cell Transplant Improves Multiple Myeloma Survival, Reduces Risk of Progression

Roswell Park Cancer Institute

2011-05-13

Philip McCarthy, Jr., MD, of Roswell Park Cancer Institute presented data from a CALGB trial at the International Myeloma Workshop. Patients receiving maintenance lenalidomide therapy had higher survival rate and lower risk of disease progression.

Health Literacy Tests Underutilized; May Improve Elderly Cancer Patients’ Care and Outcomes

University of Texas M. D. Anderson Cancer Center

2011-04-29
MD Anderson nurse recommends health practitioners assess health literacy to overcome barrier to quality care.

**AACR Awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students**

**American Association for Cancer Research (AACR)**

2011-03-25

The American Association for Cancer Research will recognize 27 recipients of the AACR-Thomas J. Bardos Science Education Award for Undergraduate Students at the AACR 102nd Annual Meeting 2011, held here from April 2 to 6.

**First Look at the Full Multiple Myeloma Genome Reveals New Insights, Discoveries**

**Dana-Farber Cancer Institute**

2011-03-21

Broad Institute and Dana-Farber scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma. The study yielded insights into the events that lead to this form of cancer and could influence the direction of research.

**Mouse Cancer Genome Unveils Genetic Errors in Human Cancers**

**Washington University in St. Louis**

2011-03-21

By sequencing the genome of a mouse with cancer, researchers at Washington University School of Medicine in St. Louis have uncovered mutations that also drive cancer in humans. The investigators are the first to sequence a mouse cancer genome, and their research is reported online March 23 in the Journal of Clinical Investigation.

**New Hope for Baby Boomers with Leukemia and Lymphoma**

**Loyola University Health System**

2011-02-17

As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

**Researchers Pinpoint How One Cancer Gene Functions**

**Mayo Clinic**
For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn’t been clear, however, is how the body’s genome sustains such destructive glitches in the first place. Now a team of Mayo Clinic scientists and collaborators provide an unprecedented glimpse of a little-understood gene, called MMSET, revealing how it enables disease-causing mutations to occur. The findings appear in the current issue of Nature.

Prototype Drug Targets Metabolism, Halts Disease That Limits Bone Marrow Transplantation

University of Michigan

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

Search term = “myeloma press releases”. First 10 results returned

1. Multiple Myeloma Press Releases
   www.ereleases.com/pr/tag/multiple-myelomaCached
   You +1’d this publicly. Undo
   NEWTOWN, Pa., March 23, 2010 — When Edwin Hill was diagnosed with Multiple Myeloma his first reaction was disbelief. He was young, healthy, in the prime of ...

2. multiple myeloma News - FierceBiotech Research
   www.fiercebiotechresearch.com/tags/multiple-myelomaCached
   You +1’d this publicly. Undo
   9 Apr 2007 – multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results ...

3. multiple myeloma News - FierceVaccines
   www.fiercevaccines.com/tags/multiple-myelomaCached
You +1’d this publicly. Undo

5 May 2011 – multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results ...

4. multiple myeloma News - FierceBiotech

www.fiercebiotech.com/tags/multiple-myelomaCached

You +1’d this publicly. Undo

multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results ...

5. multiple myeloma - Online Public Relations - Online Press Releases ...

www.widepr.com/search.html?q=multiple+myelomaCached

You +1’d this publicly. Undo


6. Cancer - Lymphoma Society

www.thecancerinfo.com/lymphoma/lymphoma_society/

You +1’d this publicly. Undo

Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. (Press Releases) The Leukemia &amp; Lymphoma Society Congratulates Corina Morariu, ...

7. Cancer - Leukemia Lymphoma Society

www.thecancerinfo.com/lymphoma/leukemia_lymphoma_society/Cached

You +1’d this publicly. Undo

Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. (Press Releases ... Show more results from thecancerinfo.com

8. myeloma News - FiercePharma

www.fiercepharma.com/tags/myelomaCached

You +1’d this publicly. Undo
17 Oct 2008 – myeloma Press Releases. European Commission Adopts European Medicines Agency’s (EMA) Recommendation to Lift the Suspension of the Marketing ...

9. lymphoma
top-health.smsprikol.com/letter-l/lymphoma.htmlCached

You +1’d this publicly. Undo

Fighting leukemia, lymphoma, Hodgkin’s disease and myeloma. ... (Press Releases) The Leukemia & Lymphoma Society Offers Program on Childhood Leukemia and ...

10. Leukemia
www.eastcairn.com/Diseases/leukemia.htmlCached

You +1’d this publicly. Undo

Fighting leukemia, lymphoma, Hodgkin’s disease and myeloma. ... Press Releases) The Leukemia & Lymphoma Society and the Leukemia Research Fund of Canada ...

IV. US Food and Drug Administration Info on Myeloma

Drugs@FDA Database

Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed


October 2011

None

September 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-WASH (NDA # 022305)</td>
<td>PURIFIED WATER</td>
<td>5</td>
<td>5</td>
<td>NIAGARA PHARMA</td>
<td>09/01/2011</td>
</tr>
<tr>
<td>Product Name</td>
<td>Brand Name</td>
<td>Inc. Code</td>
<td>Inc. Name</td>
<td>Date</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td><strong>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</strong></td>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE</td>
<td>4</td>
<td>MATRIX LABS LTD</td>
<td>09/08/2011</td>
<td></td>
</tr>
<tr>
<td><strong>LAMIVUDINE; ZIDOVUDINE (NDA # 201151)</strong></td>
<td>LAMIVUDINE; ZIDOVUDINE</td>
<td></td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
<td></td>
</tr>
<tr>
<td><strong>MEMANTINE HYDROCHLORIDE (NDA # 200155)</strong></td>
<td>MEMANTINE HYDROCHLORIDE</td>
<td></td>
<td>TORRENT PHARMS</td>
<td>09/27/2011</td>
<td></td>
</tr>
<tr>
<td><strong>CLOBETASOL PROPIONATE (NDA # 201402)</strong></td>
<td>CLOBETASOL PROPIONATE</td>
<td></td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
<td></td>
</tr>
<tr>
<td><strong>August 2011</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GEMCITABINE (NDA # 200795)</strong></td>
<td>GEMCITABINE HYDROCHLORIDE</td>
<td>3</td>
<td>HOSPIRA INC</td>
<td>08/04/2011</td>
<td></td>
</tr>
<tr>
<td><strong>ROSUVASTATIN ZINC (NDA # 202172)</strong></td>
<td>ROSUVASTATIN ZINC</td>
<td>2</td>
<td>WATSON LABS INC</td>
<td>08/04/2011</td>
<td></td>
</tr>
<tr>
<td><strong>COMPLERA (NDA # 202123)</strong></td>
<td>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE</td>
<td>4</td>
<td>GILEAD SCIENCES INC</td>
<td>08/10/2011</td>
<td></td>
</tr>
<tr>
<td><strong>ZELBORAF (NDA # 202429)</strong></td>
<td>VEMURAFENIB</td>
<td>1</td>
<td>HOFFMAN LA ROCHE</td>
<td>08/17/2011</td>
<td></td>
</tr>
</tbody>
</table>
### Myeloma HittPack™

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADCETRIS (BLA # 125388)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADCETRIS (BLA # 125399)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIRAZYR (NDA # 022150)</td>
<td>ICATIBANT ACETATE</td>
<td>1</td>
<td>P</td>
<td>SHIRE ORPHAN THERAPY</td>
<td>08/25/2011</td>
</tr>
<tr>
<td>NUCYNTA ER (NDA # 200533)</td>
<td>TAPENTADOL HYDROCHLORIDE</td>
<td>3</td>
<td>S</td>
<td>ORTHO MCNEIL JANSSEN</td>
<td>08/25/2011</td>
</tr>
<tr>
<td>XALKORI (NDA # 202570)</td>
<td>CRIZOTINIB</td>
<td>1</td>
<td>P</td>
<td>PFIZER</td>
<td>08/26/2011</td>
</tr>
</tbody>
</table>

### July 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCAPTA NEOHALER (NDA # 022383)</td>
<td>INDACATEROL MALEATE</td>
<td>1</td>
<td>S</td>
<td>NOVARTIS</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>XARELTO (NDA # 022406)</td>
<td>RIVAROXABAN</td>
<td>1</td>
<td>S</td>
<td>JOHNSON AND JOHNSON</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>BRILINTA (NDA # 022433)</td>
<td>TICAGRELOR</td>
<td>1</td>
<td>S</td>
<td>ASTRazeneca LP</td>
<td>07/20/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM (NDA # 201370)</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM PRESERVATIVE FREE</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
</tbody>
</table>
**V. Guidelines in Myeloma**

**National Guidelines Clearinghouse--Guidelines.gov**

[www.guidelines.gov](http://www.guidelines.gov); Search criteria = “myeloma” all years, sorted by relevance, first 20 listed

1. **Thalidomide in multiple myeloma.** 2010 Jan 20. NGC:008036  
   [View](http://www.guidelines.gov)  
   All guidelines by the developer(s)

   [View](http://www.guidelines.gov)  
   All guidelines by the developer(s)
   British Committee for Standards in Haematology - Professional Association. View all guidelines by the developer(s)

   American Society of Clinical Oncology - Medical Specialty Society. View all guidelines by the developer(s)

5. **Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.** 2009 Jun. NGC:007383
   National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

   Finnish Medical Society Duodecim - Professional Association. View all guidelines by the developer(s)

7. **UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).** 2009 Oct. NGC:007594
   British Committee for Standards in Haematology - Professional Association. View all guidelines by the developer(s)

8. **Guideline for the use of imaging in the management of myeloma.** 2007 Apr. NGC:006178
   British Committee for Standards in Haematology - Professional Association. View all guidelines by the developer(s)

   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]
View all guidelines by the developer(s)

New Zealand Guidelines Group - Nonprofit Organization. View all guidelines by the developer(s)

American Society of Clinical Oncology - Medical Specialty Society; American Society of Hematology - Medical Specialty Society. View all guidelines by the developer(s)

National Collaborating Centre for Cancer - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

American Cancer Society - Disease Specific Society. View all guidelines by the developer(s)

British Committee for Standards in Haematology - Professional Association.
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

19. **Metastatic spinal cord compression. Diagnosis and management of adults at risk of and with metastatic spinal cord compression.** 2008 Nov. NGC:007194
National Collaborating Centre for Cancer - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)

---

**National Comprehensive Cancer Network**

Free password required

[www.nccn.org](http://www.nccn.org)

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Multiple Myeloma


**American Society of Clinical Oncology**

[www.asco.org](http://www.asco.org)

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the role of bisphosphonates in multiple myeloma

[http://jco.ascopubs.org/content/25/17/2464.full.pdf](http://jco.ascopubs.org/content/25/17/2464.full.pdf)
VI. Conferences and Medical Associations for Myeloma

Conferences

- American Society of Hematology annual meeting [http://hematology.org/Meetings/Annual-Meeting/](http://hematology.org/Meetings/Annual-Meeting/)
- Annual European Society of Medical Oncology (ESMO) Congress [http://www.esmo.org/](http://www.esmo.org/)

Medical Associations

- American Society of Hematology (ASH)
- International Myeloma Foundation
- Multiple Myeloma Research Foundation (MMRF)
- American Cancer Society (ACS)
- American Society of Clinical Oncology (ASCO)
- National Cancer Institute (NCI)
- Association of Cancer Online Resources
- European Hematology Association
- Myeloma Euronet

VII. Key Opinion Leaders in Myeloma

A listing of key opinion leaders (KOLs) in myeloma who have participated in recent CME activities available online. Where possible, the sponsor information has been listed.

- **Sagar Lonial, MD**, Associate Professor; Vice Chair of Clinical Affairs, Hematology and Medical Oncology; Director, Translational Research B-Cell Malignancy Program, Winship Cancer Institute, Emory University, Atlanta, Georgia. Served as an advisor or consultant for: Bristol-Myers Squibb Company; Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc. Served as a speaker or a member of a speakers bureau for: Merck & Co., Inc.

- **Jonathan L. Kaufman, MD**, Assistant Professor, Hematology and Medical Oncology, Associate Director, Hematology and Medical Oncology Fellowship Program, Winship Cancer Institute, Emory University, Atlanta, Georgia. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Keryx
Biopharmaceuticals Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.

- **Antonio Palumbo, MD**, Chief, Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy. Served as an advisor or consultant for: Celgene Corporation; Janssen Biotech, Inc.

- **Sergio Giralt, MD**, Chief, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Genzyme Pharmaceuticals; Amgen Inc.

- **Kenneth C. Anderson, MD**, Director, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute; Kraft Family Professor of Medicine, Harvard Medical School, Boston, Massachusetts. Served as an advisor or consultant for: Bristol-Myers Squibb Company; Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Merck & Co., Inc.; Onyx Pharmaceuticals, Inc. Owns stocks, stock options, or bonds from: Acetylon.

- **Ruben Niesvizky, MD**, Associate Professor of Medicine; Director, Myeloma Service, Division of Hematology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, New York. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.

- **Paul G Richardson, MD**, Clinical Director, Jerome Lipper Center for Multiple Myeloma; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation

- **James R. Berenson, MD**, Medical and Scientific Director, Institute for Myeloma and Bone Cancer Research, West Hollywood, California. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Cephalon, Inc.; OrthoBiotech Products, L.P.; Novartis Pharmaceuticals Corporation; Amgen Inc.; Curagen; CytoGen Corporation; Seattle Genetics, Inc. Received grants for clinical research from: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Cephalon, Inc.; Novartis Pharmaceuticals Corporation; Amgen Inc.; Curagen; CytoGen Corporation; Seattle Genetics, Inc.; Pfizer Inc.; ZIOPHARM Oncology, Inc. Served as a speaker or a member of a speakers bureau for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Cephalon; OrthoBiotech Products, L.P.; Novartis Pharmaceuticals Corporation.

- **Sundar Jagannath, MD**, Director of the Multiple Myeloma Program, Professor of Medicine (Hematology and Medical Oncology), The Tisch Cancer Institute, Mount Sinai School of Medicine, New York. Supported by an educational grant from Onyx Pharmaceuticals, Inc.

- **Morie A. Gertz, MD**, Division of Hematology, Mayo Clinic, Rochester, MN. Member of the Millennium Advisory Board, received research support from Genzyme, and received honoraria from Millennium, Easi, Celgene, and Amgen.

**VIII. Clinical Trials in Progress in Myeloma**
Clinical trials.gov

Search criteria - myeloma | Open Studies | Exclude Unknown | Phase III, IV

63 of 63 studies listed

1. **Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma**

   **Condition:** Multiple Myeloma

   **Interventions:** Biological: MAGE-A3; Biological: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY

2. **Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma**

   **Condition:** Multiple Myeloma

   **Intervention:** Drug: pomalidomide

3. **Study to Compare Efficacy and Safety of Pomalidomide Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma**

   **Condition:** Multiple Myeloma

   **Interventions:** Drug: pomalidomide; Drug: dexamethasone

4. **Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma**

   **Condition:** Multiple Myeloma and Plasma Cell Neoplasm

   **Interventions:** Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide

5. **High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy**

   **Condition:** Multiple Myeloma and Plasma Cell Neoplasm

   **Interventions:** Drug: cyclophosphamide; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation

6. **Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma**
Conditions:  Multiple Myeloma;  Auto Stem Cell Transplant

Intervention:  Drug: Bortezomib

7  **Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients**

Condition:  Multiple Myeloma

Interventions:  Drug: Perifosine;  Drug: Perifosine Placebo;  Drug: Bortezomib;  Drug: Dexamethasone

8  **Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma**

Condition:  Multiple Myeloma

Interventions:  Drug: Panobinostat;  Drug: Bortezomib;  Drug: Dexamethasone;  Drug: Placebo

9  **Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma**

Condition:  Multiple Myeloma and Plasma Cell Neoplasm

Interventions:  Drug: bortezomib;  Drug: dexamethasone;  Drug: lenalidomide

10  **Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma**

Conditions:  Cancer;  Hematologic Malignancies;  Multiple Myeloma;  Oncology;  Bone Metastases;  Multiple Myeloma Bone Lesions

Interventions:  Drug: Denosumab;  Drug: Zoledronic acid

11  **Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma**

Condition:  Multiple Myeloma

Intervention:  Procedure: Single ASCT with Thalidomide maintenance

12  **Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma**

Conditions:  Multiple Myeloma;  Compression Fracture of Vertebral Column
Intervention: Procedure: Kyphoplasty/Vertebral Augmentation (Device-StabiliT)

13 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone

14 Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib, Melphanal, Prednisone (VMP); Drug: 1 or 2 cycle(s) HDM (High Dose Melphanal); Drug: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)

15 Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment

Condition: Multiple Myeloma
Intervention: Other: tandem autologous transplantation

16 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Other: clinical observation

17 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

Condition: Multiple Myeloma
Interventions: Drug: zoledronic acid; Other: No treatment control

18 Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone

19 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Condition: Multiple Myeloma
Intervention: Other: Any MMY treatment

20 Autologous Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Thalidomide; Drug: Melphalan; Biological: Granulocyte-colony stimulating factor; Drug: Dexamethasone

21 Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone; Drug: dexamethasone

22 A Study of the Effectiveness of Armadafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Conditions: Fatigue; Multiple Myeloma
Interventions: Drug: armodafinil; Drug: Placebo

23 Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide

24 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Dexamethasone; Drug: Lenalidomide; Drug: Carfilzomib

25 Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide; Drug: Melphalan+Prednisolone

26 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib, Pirarubicin, Dexamethasone; Drug: Thalidomide, Pirarubicin, Dexamethasone

27 A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma

Interventions: Drug: Placebo, Velcade and dexamethasone; Biological: Siltuximab, Velcade and dexamethasone

28 Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma

Interventions: Drug: melphalan; Drug: amifostine trihydrate; Procedure: peripheral blood stem cell transplantation; Genetic: fluorescence in situ hybridization; Procedure: bone marrow ablation with stem cell support

29 Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Condition: Multiple Myeloma

Intervention: Drug: velcade

30 UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

Condition: Multiple Myeloma

Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)

31 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications

Intervention: Drug: zoledronic acid

32 Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in
**MM Patients up to Age 65**

**Condition:** Multiple Myeloma  

**Interventions:** Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant

**33 Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy**

**Condition:** Multiple Myeloma  

**Interventions:** Drug: Emend; Drug: Placebo

**34 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma**

**Condition:** Multiple Myeloma  

**Interventions:** Procedure: Autologous bone marrow transplantation; Procedure: Allogeneic bone marrow transplantation

**35 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma**

**Condition:** Multiple Myeloma  

**Interventions:** Drug: bortezomib (Velcade); Drug: cyclophosphamide; Drug: G-CSF

**36 Imaging Young Myeloma (IMAge Jeune Myéome)**

**Condition:** Multiple Myeloma  

**Interventions:** Procedure: PET scan; Procedure: MRI

**37 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma**

**Condition:** Multiple Myeloma  

**Interventions:** Drug: carfilzomib; Drug: Best Supportive Care

**38 Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients**

**Condition:** Multiple Myeloma  

**Interventions:** Drug: Melphalan, Prednisone, Lenalidomide; Drug: Cyclophosphamide, Prednisone, Lenalidomide; Drug: Lenalidomide, dexamethasone
39  **Busulfan Plus Melphalan Versus Melphalan**

**Condition:**  Myeloma

**Interventions:**  Drug: Busulfan;  Drug: Melphalan;  Other: Questionnaire;  Drug: G-CSF;  Drug: High Dose Melphalan;  Procedure: Stem cell transplant

40  **Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects**

**Condition:**  Multiple Myeloma

**Interventions:**  Drug: Cyclophosphamide;  Drug: Lenalidomide;  Drug: Dexamethasone;  Drug: Melphalan

41  **A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients**

**Condition:**  Multiple Myeloma

**Intervention:**

42  **Pseudohyponatremia of Multiple Myeloma is True Hyponatremia**

**Condition:**  Hyponatremia of Multiple Myeloma

**Intervention:**  Other: blood test

43  **Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide**

**Condition:**  Refractory Multiple Myeloma

**Interventions:**  Drug: plerixafor;  Biological: filgrastim

44  **Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years**

**Conditions:**  Patients Newly Diagnosed With Symptomatic Multiple Myeloma;  Patients Aged up to 65 Years;  Progression Free Survival Prolongation;  Time to Progression;  Overall Survival

**Intervention:**  Drug: Lenalidomide, Bortezomib

45  **ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain**
Conditions: Bone Metastases; Multiple Myeloma

Interventions: Device: ExAblate 2000; Device: Sham

46 Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

Condition: Chronic Renal Failure With Uremic Nephropathy

Interventions: Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen; Drug: Bortezomib + Dexamethasone regimen; Device: HCO group; Device: conventional high-flux dialyzer

47 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma

Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Biological: Elotuzumab

48 Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma

Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab

49 The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma

Condition: Multiple Myeloma

Interventions: Drug: Lenalidomide, Dexamethasone; Drug: Lenalidomide, Dexamethasone, PB SCT

50 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma

Conditions: Bone Cancer; Secondary Malignant Neoplasm of Bone; Pain

Interventions: Device: Exablate treatment; Radiation: Radiation

51 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific

Intervention: Other: educational intervention

52 Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor

Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy

53 Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Condition: Multiple Myeloma

Intervention: Drug: bortezomib + dexamethasone

54 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: melphalan

55 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders

Intervention: Biological: Donor lymphocyte preparation depleted of host functional alloreactive T-cells

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Conditions: Multiple Myeloma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Non Hodgkin's Lymphoma; Waldenstroms; Mantle Cell Lymphoma

Interventions: Drug: Fludarabine; Radiation: Total Body Irradiation; Other: Infusion of Stem Cells

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Multiple Myeloma

Interventions: Radiation: Total Body Irradiation; Drug: Fludarabine; Procedure: Recipient Leukocyte Infusion

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Conditions: Non-Hodgkin's Lymphoma; Multiple Myeloma

Interventions: Drug: Plerixafor; Drug: Filgrastim

Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

Condition: Cancer

Interventions: Drug: ketamine hydrochloride; Other: pharmacogenomic studies; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment

Exercise During Chemotherapy for Patients With Hematological Malignancies
Conditions: Hematological Diseases; Hematological Malignancies

Interventions: Other: Aerobic exercise; Behavioral: Fatigue counseling

62 Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

Condition: Cancer

Interventions: Dietary Supplement: Vitamin D; Dietary Supplement: Calcium

63 A Trial for Systemic Light-chain (AL) Amyloidosis

Condition: AL Amyloidosis

Intervention: Drug: BMDex

IX. PubMed Search in Myeloma


Search = myeloma, published in the last 180 days, English only

Randomized Controlled Trials

Results: 7

1. Safety and efficacy of zoledronic acid in multiple myeloma.

Tanimoto T, Matayoshi T, Yagasaki F, Takeuchi K, Kami M.


PMID:

21704866

[PubMed - indexed for MEDLINE]

Related citations

2. Safety and efficacy of zoledronic acid in multiple myeloma.

Kyrgidis A, Tzellos TG.

PMID:
21704864

[PubMed - indexed for MEDLINE]

Related citations


PMID:
21507715

[PubMed - indexed for MEDLINE]

Related citations


PMID:
21402611

[PubMed - indexed for MEDLINE]

Related citations
5. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.


PMID: 21366694

[PubMed - indexed for MEDLINE]

Related citations

6. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.


PMID: 21328327

[PubMed - indexed for MEDLINE]

Related citations

7. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.


PMID:
1. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC.
PMID: 21888257

Landgren O, Korde N.
PMID: 21888256
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).


PMID: 21888255

[PubMed - indexed for MEDLINE]

Related citations

4. Multiple myeloma: diagnosis and orthopaedic implications.

PMID: 21724920

[PubMed - indexed for MEDLINE]

Related citations

5. Fibroblast growth factors and their receptors in cancer.

PMID: 21711248

[PubMed - indexed for MEDLINE]

Related citations
6. Translational development of vaccination strategies in follicular NHL.

Sakamaki I, Qin H, Kwak LW.


PMID: 21658625

[PubMed - indexed for MEDLINE]

Related citations

7. Notch-ing from T-cell to B-cell lymphoid malignancies.

Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R.


PMID: 21652011

[PubMed - indexed for MEDLINE]

Related citations

8. Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.


PMID: 21606441

[PubMed - indexed for MEDLINE]

Related citations


PMID: 21577327
[PubMed - indexed for MEDLINE]
Free PMC Article
Free full text Related citations

10. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.


PMID: 21575928
[PubMed - indexed for MEDLINE]
Related citations


PMID:


PMID:
21569004

[PubMed - indexed for MEDLINE]


Weiss JS, Khemichian AJ.


PMID:
21540632

[PubMed - indexed for MEDLINE]

14. \(\gamma\delta\) T-cell immunotherapy for lung cancer.

Yoshida Y, Nakajima J, Wada H, Kakimi K.
15. A clinical perspective of IL-1β as the gatekeeper of inflammation.
Dinarello CA.
PMID: 21523780
[PubMed - indexed for MEDLINE]

Related citations

PMID: 21517805
[PubMed - indexed for MEDLINE]

Related citations

17.
Vertebra plana in an adolescent caused by multiple myeloma: a case report and review of the literature.

Greenleaf RM, Ricciardella LF, Latona CR, Sangimino MJ.


PMID:
21508272

[PubMed - indexed for MEDLINE]

Related citations

  18. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.

Keating GM.


PMID:
21504247

[PubMed - indexed for MEDLINE]

Related citations


Lourbopoulos A, Ioannidis P, Balogiannis I, Stavrinou P, Koletsas T, Karacostas D.


PMID:
21498133

[PubMed - indexed for MEDLINE]

Related citations
20. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.


PMID: 21497966

[PubMed - indexed for MEDLINE]

Related citations


Pozzi S, Raje N.


PMID: 21493759

[PubMed - indexed for MEDLINE]

Related citations


Ponticelli C, Moroni G, Glassock RJ.


PMID: 21493742

[PubMed - indexed for MEDLINE]

Related citations
23. Advances in imaging and the management of myeloma bone disease.

Terpos E, Moulopoulos LA, Dimopoulos MA.


_PMID:_

21483016

[PubMed - indexed for MEDLINE]

Related citations


_PMID:_

21482986

[PubMed - indexed for MEDLINE]

Related citations


Moreau P, Avet-Loiseau H, Harousseau JL, Attal M.


_PMID:_

21482979

[PubMed - indexed for MEDLINE]

Related citations

Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG.
PMID: 21482978
[PubMed - indexed for MEDLINE]

Related citations

27. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

PMID: 21470070
[PubMed - indexed for MEDLINE]

Related citations


Korde N, Kristinsson SY, Landgren O.
PMID: 21441462
Related citations

29. Pomalidomide therapy for myeloma.

Schey S, Ramasamy K.


PMID:

21413906

Related citations

30. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.

Kumar S.


PMID:

21394431

Related citations

31. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.

Corthay A, Lorvik KB, Bogen B.


PMID:

21388431
Related citations

32. Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Mateos MV, San-Miguel J.

PMID: 21347656

Related citations

33. New immunomodulatory drugs in myeloma.
Lacy MQ.

PMID: 21327565

Related citations

34. Bisphosphonates in oncology.
Coleman RE, McCloskey EV.

PMID: 21320652
35. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Dinarello CA.


PMID: 21304099


Albarracin F, Fonseca R.


PMID: 21295388

37. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.


PMID:
Related citations


PMID:
21292778

[PubMed - indexed for MEDLINE]

Related citations


PMID:
21292777

[PubMed - indexed for MEDLINE]

Related citations
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.


PMID:
21292775

[PubMed - indexed for MEDLINE]

Related citations

41. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.

Jantunen E, Fruehauf S.


PMID:
21217789

[PubMed - indexed for MEDLINE]

Related citations

42. Teratogenic effects of thalidomide: molecular mechanisms.

Ito T, Ando H, Handa H.


PMID:
21207098

[PubMed - indexed for MEDLINE]
Related citations

43. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.


PMID:

20863623

[PubMed - indexed for MEDLINE]

Related citations

Editorials

Results: 3

1. Identification of genetic parameters associated with disease progression in plasma cell myeloma.

Bacher U, Binder M.


PMID:

21924493

[PubMed - as supplied by publisher]

Related citations

2. Protein Z concentration in multiple myeloma patients.
Bolkun L, Piszcz J, Oleksiuk J, Luksza E, Galar M, Szumowska A, Kloczko J.


**PMID:**

21868070

[PubMed - as supplied by publisher]

**Related citations**

3.

*Humbling snapshots.*

Kellerman PS.


**PMID:**

21601122

[PubMed - indexed for MEDLINE]

**Related citations**